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Abstract Very few studies have investigated dose re-
sponse of aspirin and agreement of different platelet
function assays in children. One hundred five children
were studied at baseline and after interventional cardiac
catheterization during aspirin treatment and, in cases of
aspirin resistance (AR), after dose increase. Results from
arachidonate-induced aggregation (AA) were compared
with aggregation induced by ADP, PFA-100 closure
times (CTs), urinary 11-dehydro-thromboxane B2
(urinary 11-dhTxB2) levels, and Impact-R % surface
coverage. Aspirin at 2–5 mg/kg/day inhibited platelet
function in a large majority. While 19 % showed bruis-
ing and mild epistaxis, no thrombotic complications were
recorded. AR was detected by AA in seven children
(6.7 %). After dose increase, the majority showed inhi-
bition by aspirin. Infants had higher urinary 11-dhTxB2
baseline levels; this assay showed some correlation with
AA. Both assays manifested high sensitivity and speci-
ficity for aspirin while inferior results were found for the
other assays. With the PFA-100, 15.2 % of patients were
found to have AR, but this corresponded to AR by AA
in only one of seven children.
Conclusion: While there was poor agreement among as-
says, AA and urinary 11-dhTxB2 show good specificity for
the monitoring of aspirin therapy in children. Aspirin at 2–
5 mg/kg inhibits platelet function; AR in children is rare and
can be overcome by dose increase.
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Introduction
In children, aspirin is the most commonly used anti-platelet
agent for the prevention of arterial thrombotic events. It is
commonly used for the prevention of stroke recurrence and
prophylactically after interventional cardiac catheterization
(ICC) and cardiac surgery [3, 6, 16, 23, 26, 35, 36].
Aspirin is usually administered at a dose ranging from 2 to
10 mg/kg/day; higher aspirin doses are only used as anti-
inflammatory treatment for children with Kawasaki disease
[26, 35]. Still, a relatively small number of clinical trials
assessing the monitoring and efficacy of aspirin have been
conducted in pediatric patients. Current protocols for anti-
thrombotic prophylaxis for ICC in children have been devel-
oped according to protocols from adults [22, 23, 26, 36]. In
adults after ICC, thrombus formation on atrial septal defect
and patent foramen ovale closure devices has been reported in
0–7 % of patients and differed between devices [19].
In the past, studies on both adults and children have report-
ed a variability in aspirin response called aspirin “resistance”
(AR). While this has led to concern among patients and phy-
sicians about the efficacy of aspirin, there is ongoing discus-
sion as to the mechanisms responsible for the variability in
anti-platelet effects and the role of different laboratory assays
in the monitoring of aspirin therapy. While a failure of aspirin
to produce a response on laboratory measures has been report-
ed in 5–56 % of adult cases, depending on the clinical setting
and the laboratory method used, an inability of aspirin to pro-
tect individuals from arterial thrombosis is found at a lower
frequency of 4–10 % [7, 11, 12]. The poor correlation of
different platelet function tests and the prediction of a throm-
botic risk by laboratory measures of AR has been debated in
the literature [5, 7, 10, 13, 15, 24, 30].
So far, four pediatric studies (one published in abstract
form) have investigated AR; in each, children receiving aspi-
rin for a variety of indications (e.g., stroke, cardiac surgery,
and thrombocytosis) were included. For the determination of
aspirin responsiveness, mostly global platelet function or
point-of-care tests, i.e., the platelet function analyzer PFA-
100® or the VerifyNow Aspirin® system, and urinary 11-
dehydro-thromboxane B2 (urinary 11-dTxB2) level measure-
ments were used. An AR prevalence of 2.3–26 % was report-
ed and was highly assay dependent. Again, only one study
described children with thrombotic events; however, the au-
thors were unable to correlate this with the laboratory response
to aspirin [6, 16, 29, 40].
In view of the incomplete and limited amount of data avail-
able, the aims of this study were (1) to evaluate the usefulness
and assay agreement of different laboratory tests for the deter-
mination of aspirin response, (2) to determine the prevalence
of AR, and (3) to provide preliminary information about effi-
cacy and safety of aspirin therapy, in a well-defined cohort of
pediatric patients undergoing interventional cardiac
catheterization.
Patients and methods
This prospective study was performed at the University
Children’s Hospital in Zurich, Switzerland, and was approved
by the regional Ethics Committee. Written informed consent
was obtained from patients and/or parents as appropriate; en-
rollment was between August 2006 and October 2010.
Children with congenital heart defects undergoing ICC with
dilatation of single valve stenosis, stent implantation or dila-
tation of isolated pulmonary artery or aortic stenosis, or device
closure of atrial or ventricular septal defects or patent arterial
duct, and requiring aspirin therapy for 3–6 months were in-
cluded. Children were excluded from the study if they had one
of the following conditions: a complex or univentricular heart
malformation; dysmorphic syndrome interfering with platelet
function or number, such as Noonan and thrombocytopenia-
absent radius syndrome; known congenital metabolic or hem-
orrhagic disorders; known anemia (hemoglobin<100 g/l) and/
or thrombocytopenia (platelet<150×109/L); known aspirin
allergy; intake of other medications interfering with platelet
function; non-compliance; and parents unwilling to consent to
the study. A detailed bleeding history was taken in all study
subjects, and children with a positive bleeding history or a
known bleeding disorder were excluded.
Interventional cardiac catheterization and follow-up
During ICC, children received a bolus of 100 IU/kg
unfractionated heparin intravenously after establishing femo-
ral vascular access, followed by a second bolus of 50 IU/kg
after 60 min. After ICC, children received one dose of low
molecular weight heparin subcutaneously at a dose of 1 mg/kg
and aspirin was started the evening after ICC with a single
daily dose of 2–5 mg/kg orally, rounded to the nearest half-
tablet size. Aspirin therapy was continued for a total of
3 months after closure of patent arterial duct or balloon dila-
tation of valvular stenosis, and for 6 months in all other cases.
Routine follow-up visits were carried out 1, 3, and 6 months
after ICC and included physical examination, electrocardio-
gram, pulse oxymetry, and two-dimensional transthoracic
echocardiography. Compliance for aspirin intake, bleeding
events, and side effects were assessed by structured interview
and questionnaire. Laboratory response to aspirin therapy was
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measured 4–6 weeks after closure of patent arterial duct or
balloon dilatation of valvular stenosis and 10–12 weeks after
all other procedures.
Blood sampling and laboratory investigations
Peripheral blood samples were collected by venepuncture pri-
or to cardiac catheterization, and 4–6 or 10–12 weeks after the
procedure during a regular follow-up visit at the cardiac out-
patient clinic. In children showing AR by arachidonate-
induced aggregation (AA), the aspirin dose was increased to
6–10 mg/kg/day and additional testing was performed 1–
3 weeks after dose increase.
Ten to 12 mL venous blood was collected into tubes con-
taining 0.106 or 0.129M (for PFA-100) sodium citrate as anti-
coagulant (S-monovettes, Sarstedt, Nürnberg Germany); for
blood cell counts, EDTA anti-coagulant was used. The sam-
ples were kept at room temperature and studied within 4 h of
collection. Additionally, 5–10 mL urine was collected at the
time of each blood sampling.
Platelet aggregometry Platelet aggregation, which evaluates
responsiveness to different platelet-activating agents, e.g., AA
and ADP, by measuring changes in light transmission in rap-
idly stirred citrated platelet-rich plasma, was performed with a
four-channel aggregometer (APACT 4004, LABuTec,
Ahrensburg, Germany). According to platelet aggregometry,
AR was defined as >20 % aggregation response to 0.5 mM
arachidonate and >70 % response to 10 μM ADP. AA has
demonstrated a high and specific sensitivity to aspirin
and is used as the gold standard for the determination of
aspirin responsiveness in this and in other adult studies
[12, 17, 31].
Urinary 11-dhTxB2 Production of this urinary thromboxane
metabolite is suppressed by the inhibition of thromboxane
synthesis by aspirin. Levels were measured using a quantita-
tive enzyme-linked immunoassay kit (AspirinWorks1,
Corgenix, Inc., Broomfield, CO) at the Hamilton
Haemostasis Reference Laboratory, Hamilton, ON, Canada).
Urine specimens were frozen within 2–4 h of collection at
−70 °C for storage and were shipped with dry ice. AR was
defined in comparison with urinary 11-dhTxB2 baseline
levels: On aspirin, a level above the 10th percentile of age-
correlated urinary 11-dhTxB2 excretion at baseline was con-
sidered as AR.
PFA-100® PFA-100 closure times (CTs) with the collagen/
epinephrine (Col/Epi) cartridge are prolonged after ingestion
of aspirin in the majority of patients. CT measurements were
performed using citrated whole blood according to the manu-
facturer’s instructions (Siemens Healthcare Diagnostics Inc.,
Erlangen, Germany). A normal Col/Epi CT (<164 s) during
aspirin therapy was considered as AR [4].
Impact-R This cone and plate analyzer determines platelet
adhesion to a polystyrene surface by a photodigital sensor
under laminar flow. The manufacturer has developed a meth-
od to detect platelet inhibition by aspirin and has validated this
method in adults. Analysis with the Impact-R® (DANED SA,
Beersel, Belgium) was performed according to the manufac-
turer’s instructions: The percentage of surface covered (% SC)
provides information about platelet adhesion and aggregation.
Aspirin response was investigated after addition of 0.275 μM
arachidonate as the agonist, and AR was documented by a
reduced SC to ≤3.4 % [33, 34].
Statistical analyses
Data are presented as means±SD for normally distribut-
ed data and otherwise, as median and interquartile range
(IR). Student’s t test and the Wilcoxon test were used to
compare continuous variables between two groups. The
Fisher exact test was used for comparing categorical
data. Correlation was calculated using Spearman’s cor-
relation coefficient. Receiver operator characteristic
(ROC) analysis was used to determine the sensitivity
and specificity of the laboratory assays used. The agree-
ment between the aspirin response assessed by AA and
the other tests was evaluated using Cohen’s kappa co-
efficient [2]. P values<0.05 were considered significant.
Prism version 4.0 and QuickCalcs (GraphPad Software,
CA, USA) and SPSS version 15.0 (SPSS, Zurich,
Switzerland) were used for data analysis.
Results
Patient population
Of 150 children for whom informed consent was obtained, 45
were excluded for the following reasons: diagnosis of von
Willbrand disease (VWD) (n=1) and history of relevant pre-
vious bleeding episodes obtained only after inclusion (n=2);
use of another medication interfering with platelet function
(n=5); poor venous access (n=3); consent withdrawal during
the study (n=2); decision by the cardiologist to cancel the ICC
(n=3), to perform open heart surgery (n=3), not to give aspi-
rin (n=2), or to administer clopidogrel (n=1); and lost to
follow-up (n=20). Three children were excluded, as venous
(n=2) or arterial (n=1) femoral thrombosis occurred during
the ICC procedure requiring low molecular weight heparin
therapy after ICC. Interventional cardiac catheterization was
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performed on the remaining 105 children; for diagnoses for
ICC, see Table 1.
Clinical outcomes
Occasional non-compliance with aspirin intake was reported
by 25 (23.8 %) of the 105 children, who forgot aspirin for 1
(n=11), 2–3 (n=5), 4–7 (n=2), or for “several days” (n=7).
However, none of the patients with AR according to AA re-
ported any non-compliance. Mean baseline aspirin dose per
kilogram body weight did not differ significantly between
children with normal aspirin response and AR (Table 1).
During aspirin therapy and at any follow-up after ICC, none
of the study subjects showed clinical or echocardiographic
signs of thromboembolism at the occlusion or stent insertion
site. Minor bleeding events were reported in 20 (19 %) chil-
dren, including mild epistaxis in 12 children (11.4 %), of
whom one had cauterization of locus Kisselbachii, two
stopped aspirin intake for 3 days, and in one, the aspirin dose
was reduced by 25%. In eight children (7.6 %), easy bruising,
unusual hematoma, and prolonged wound bleeding were re-
ported. The median age of children with minor bleeding
symptoms during aspirin was significantly lower (4.2 years)
than that of children without bleeding (8.8 years; p=0.014). In
three out of five children who had an aspirin dose increase (see
below), minor bleeding events occurred only after this
increase.
Laboratory results
Blood samples on aspirin were collected after a mean
(median) follow-up time of 4.8 (5.1) weeks for children after
patent arterial duct closure or balloon dilatation of valvular
stenosis, and 14.6 (13.8) weeks in all other cases. Routine
laboratory results at baseline, for all children, children with
AR by AA, and children with AR identified by PFA-100 CTs,
are presented in Table 1.
Platelet aggregation At baseline, 1 % of children showed
abnormal response to AA (<80 % aggregation), and 11 % to
ADP (<70 % aggregation). During aspirin therapy, AR was
detected in 7 (6.7 %) children according to AA and in 61
(58 %) according to aggregation induced with 10 μM ADP
(Table 2). Only one of the seven children with AR according
to AA also had AR according to ADP-induced aggregation.
After aspirin dose increase to the five available children with
AR according to AA, four now demonstrated a normal re-
sponse to aspirin, while only one child still had AR, docu-
mented by an AA aggregation of 95 % (the other two children
with AR according to AAwere unavailable for a dose increase
or for additional follow-up testing).
Urinary 11-dhTxB2 Levels were measured at baseline (n=
105) and during aspirin treatment (n=54). As higher urinary
11-dhTxB2 levels were found in younger children, age-
specific levels for normal urinary 11-dhTxB2 excretion were
Table 1 Clinical and laboratory
characteristics at baseline for all
patients, for aspirin “resistant”
patients (AR) according to
arachidonate-induced aggregation
(AA), and according to PFA-100
collagen-epinephrine closure
times (PFA)
Results are presented as mean±
SD if not stated otherwise.
Student’s t test results are given
for statistically significant
differences (p<0.05) only
ICC intervent ional cardiac
catheterization, ASD atrial-septal
defect, VSD ventricular-septal de-
fect, PAD patent arterial duct,
VWF:RCo von Wil lebrand
factor:ristocetin cofactor






Median age (years, range) 7.6 (0.1–19.8) 5.3 (4.8–16.5) 6.8 (2.8–15.7)
Sex (M:F) 49:56 2:5 5:11
Diagnosis for ICC (n)
ASD 36 2 11
VSD 7 – –
PAD 20 – 3
Vascular malformation of pulmonary
artery (stent implantation)
11 2 1
Coarctation of aortic arch 18 2 1
Other vascular 2 – –
malformation – –
Aortal valve stenosis 3 – –
Pulmonary valve stenosis 8 1 –
Mean aspirin dose (mg/kg/day) 3.2±1.2 2.9±0.8 3.3±1.2
Hematocrit (%) 38±4 38±2 39±4
Platelet count (×109/L) 285±61 298±46 282±39
INR 1.08±0.1 1.08±0.06 1.07±0.06
PTT (s) 35.7±4.4 34.3±2.7 35.3±2.8
VWF:RCo (%) 94.5±20.7 99.7±23.6 104.4±19.2
936 Eur J Pediatr (2015) 174:933–941
established (Fig. 1). Before aspirin intake, the median urinary
11-dhTxB2 (ng/mmol creatinine) was 517.5 (IR 407-753; n=
8) in children under 2 years, 297 (IR 205-363; n=37) for 2–
<6 years, 221 (IR 179-268; n=24) for 6 to 12 years, and 146
(IR 96.5-187.8; n=36) in children over 12 years of age
(P<0.001 for all age groups). During aspirin therapy, median
urinary 11-dhTxB2 decreased significantly (P<0.001). A
comparison of results at baseline and during aspirin therapy
for each age group is presented in Fig. 1. AR, defined as
urinary 11-dhTxB2 levels on aspirin above the 10th percentile
of baseline levels, was found in seven (12.9 %) children.
Comparing AA and urinary 11-dhTxB2 excretion, five of
the seven children with AR according to urinary 11-dhTxB2
also had AR according to AA (Fig. 1).
PFA-100 CTs At baseline, prolonged Col/Epi CTs were ob-
served in 29.5 % of children. During aspirin therapy, a normal
response to aspirin with a prolonged CT was present in 89
(84.8 %) children and AR was detected in 16 (15.2 %) chil-
dren. Of these, only one also had AR according to AA. In
seven children with AR according to AA, only one also had
AR according to Col/Epi CTs. Children showing prolonged
CTs at baseline demonstrated AR in only 1 out of 16 subjects
according to PFA-Col/Epi CTs but tended to have decreased
VWF:RCo levels (85.9±20.3 %, n=31, compared to those
with baseline CTs in the normal range (95.9±25.7 %, n=74;
P=0.09.). During aspirin therapy, in the 16 children with nor-
mal Col/Epi CTs, indicating AR, significantly increased von
Willebrand factor:ristocetin cofactor (VWF:RCo) levels (118
±32.6 %, n=16) were observed in comparison with children
with normal aspirin response and prolonged CTs (94.7±
25.7 %, n=89; P<0.01).
Impact-R SC These determinations were done on 95 children.
At baseline, before the start of aspirin therapy, mean SC was
10.1±5.4 % in the absence of agonist. Unexpectedly, added
arachidonate did not significantly decrease the mean SC (8.5±
Table 2 Sensitivity specificity and agreement of tests for the evaluation











AA (0.5 mM) 1 % 6.7 %c 0.98 –
Urinary 11-dhTxB2 na 12.9 %c 0.92 0.673
PFA-100 Col/Epi CT 29.5 % 15.2 %d 0.86 0.008
ADP-induced
aggregation
11 % 58 %d 0.72 0.001
Impact-R SC 31.6 % 6.3 %d 0.55 0.092
na not available
aReceiver operator characteristic (ROC) analysis: area under the curve
(AUC)
bCohen’s kappa coefficient of agreement (kappa): agreement in compar-
ison with arachidonate-induced aggregation (AA). The strength of agree-
ment is interpreted as follows: <0.20 poor; 0.21–0.60 fair–moderate;
0.61–0.80 good; >0.81–1 very good [2]
c Significant correlations were found between results from AA and uri-
nary 11-dehydro-thromboxane B2 (urinary 11-dhTxB2) levels (r=0.45; P
<0.001)
dNo correlations were seen between AA and all other laboratory methods
(PFA-100 collagen/epinephrine closure times, PFA-100 Col/Epi CT;
ADP-induced aggregation; and Impact-R surface coverage, Impact-R
SC) (r<0.1; P>0.1)
Fig. 1 Urinary 11-dehydro-thromboxane B2 (11-dhTxB2) levels. Results
at baseline before the start of aspirin (box andwhiskers: children<2 years,
n=8; 2–<6 years, n=37; 6–12 years, n=24; and >12 years, n=36) and
during aspirin treatment (dot plot, median and interquartile range, chil-
dren<2 years, n=4; 2–<6 years, n=16; 6–12 years, n=20; and >12 years,
n=14). Open squares indicate children with aspirin “resistance” accord-
ing to urinary 11-dhTxB2 (i.e., results above the 10th percentile of base-
line during aspirin treatment). The arrows identify five children who also
demonstrated aspirin resistance according to arachidonate-induced
aggregation
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4.1 %; P>0.1), and during aspirin therapy, the mean SC with
added arachidonate was similar (8.9±3.5 %) to baseline. On
aspirin, six patients (6.3 %) had SC results ≤3.4 %, indicating
AR. Of these, only one had a baseline SC ≤3.4 %, and only
one had AR according to AA and one according to the PFA-
100 Col/Epi CT.
Receiver operating characteristic (ROC) curve analysis
was utilized to assess the diagnostic performance of all five
tests (Fig. 2). AA and urinary 11-dhTxB2 levels showed high
sensitivity and specificity for aspirin (ROC area under the
curve (AUC) 0.98 and 0.92, respectively), while the ROC
AUCs were lower for PFA-100 Col/Epi CTs (0.86), aggrega-
tion induced with 10 μM ADP (0.72), and Impact-R % SC
(0.55), indicating lower sensitivity and specificity for these
tests. By the use of Cohen’s kappa coefficient of agreement,
AA and urinary 11-dhTxB2 levels demonstrated good agree-
ment between test results (Table 2).
Discussion
For children with congenital heart disease, aspirin is often
administered for the prevention of thromboembolism follow-
ing catheter interventions or surgical procedures. Only small
and uncontrolled studies on the dose response to and clinical
outcome from aspirin therapy in children have been published.
In the absence of large prospective trials, cardiologists mostly
manage pediatric patients according to published guidelines
for adults [3, 23, 26, 36].
The present study was performed in a large and well-
defined cohort of 105 pediatric patients. Following ICC, chil-
dren were treated with a standardized dose of 2–5 mg/kg oral-
ly. Using the “gold standard” test (AA), AR was detected in
6.7 %. In the majority of children with AR and who were
available for follow-up, an aspirin dose increase to 6–10mg/kg
resulted in the expected inhibition of AA. Aspirin therapy was
safe and our data might indicate that aspirin is effective in
preventing pediatric ICC patients from thromboembolism, al-
though patients not given aspirin were not studied. No differ-
ence in the ages of patients with and without AR were found
(Table 1). The influence of food ingestions and diet was not
studied in our cohort; recently, however, a reduced bioavail-
ability of aspirin due to high milk intake by adults was ob-
served [27].
In our study, no major bleeding event (i.e., gastrointestinal
or intracranial bleeding or bleeding requiring transfusion) was
observed. Still, 19 % of children had minor bleeding symp-
toms, and of those, the median age was significantly lower
than that of children without bleeding. In the seven children
after aspirin dose increase, more than half had epistaxis and
bruising. Due to the short follow-up time and small number, it
is difficult to draw conclusions from this; however, some adult
studies indicate that more severe bleeding events are seen in
patients on higher aspirin doses [32].
The strength of our study is that the anti-platelet activity of
aspirin was determined by different platelet function tests. The
aim was to evaluate the usefulness of tests commonly used in
children for the determination of aspirin response. While re-
sults from AA, the gold standard test, indicated a prevalence
of AR similar to adults, all other tests, i.e., urinary 11-dhTxB2
excretion, aggregation induced by 10 μM ADP, and the PFA-
100 CTs, showed AR at a higher frequency but, except for
urinary 11-dhTxB2 levels, also demonstrated an inferior spec-
ificity and/or sensitivity for aspirin. Our results are in keeping
with those from studies in adults, indicating a poor agreement
in between tests [5, 24, 31]. The Impact-R test, which is main-
ly used for research purposes, has been used to measure aspi-
rin response. We found that it demonstrated a high degree of
abnormal results at baseline, as also found by others, and a
weak concordance with the other tests [11].
Urinary 11-dhTxB2 levels are a commonly used measure
of thromboxane synthesis, which is suppressed by aspirin.
They have been validated as a predictive determinant of
stroke, myocardial infarction, or cardiovascular death in adults
[7, 8]. Results of this and two other studies have found higher
urinary 11-dhTxB2 levels in younger children [38, 40]. Thus,
we found it necessary to establish age-specific baseline refer-
ence values to subsequently define AR. Still, and in contrast to
all other tests, a good agreement and a moderate, but signifi-
cant, correlation was observed between urinary 11-dhTxB2
excretion and AA (r=0.45, P<0.001) (Table 2). Of the seven
children on aspirin that showed high urinary 11-dhTxB2
Fig. 2 Receiver operator characteristic (ROC) curves. Results for
0.5 mM arachidonate-induced aggregation (AA), urinary 11-dehydro-
thromboxane B2 levels (Urinary 11-dhTxB2), PFA-100 collagen/
epinephrine cartridge closure times (Col/Epi CT), aggregation induced
by 10 μM ADP (ADP), and Impact-R % surface coverage (Impact-R)
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excretion above the 10th percentile of baseline levels, five also
demonstrated AR according to AA. The determination of uri-
nary 11-dhTxB2 excretion performed with small urine sam-
ples appears to be an elegant way of testing aspirin response in
children; however, previous studies demonstrated that this test
is not specific for platelet cyclo-oxygenase activity.
Thromboxane A2 production by monocytes, erythrocytes,
and endothelial or renal cells has been described in both chil-
dren and adults; increased levels of urinary 11-dhTxB2 could
also reflect the presence of systemic disease such as severe
pulmonary disease, cyanosis, renal disease, or infections and
would interfere with the assessment of the platelet thrombox-
ane synthesis [1, 20, 41].
In our study, AR was detected in 15.2 % of children by
PFA-100 CTs. Many previous studies have investigated AR
using PFA-100 Col/Epi CTs, as these are prolonged by aspirin
[11, 14, 29, 40]. The PFA-100 is a popular test in many pedi-
atric centers given its simple use and requirement of only a
small volume of blood for testing; it can detect VWD or ab-
normal platelet function. With this test, two pediatric studies
showed quite discordant prevalence rates of AR, specifically
12 and 26 % [16, 40]. Only one of the studies compared the
PFA-100 results with AA: While no correlation was found
between the tests, AR determined by the PFA-100 was found
in 12 % and in 5 % by AA. In contrast to our study, that study
used a variety of and less standardized doses in their cohort
(0.9–8 mg/kg) and only evaluated a minority of their patients
off and on aspirin [40].
In the present study, we unexpectedly observed a high rate
of abnormal PFA-100 results at baseline. These prolonged
CTs that were seen in the light of normal platelet counts,
hematocrit, and VWF levels (Table 1) can only partially be
explained by the lower cut off for normal pediatric Col/Epi
CTs (<164 s) that we used compared with other studies [4, 16,
40]. Although only patients with a negative bleeding history
were included in our study, the presence of patients with mild
defects of primary hemostasis cannot be excluded, as mild
platelet dysfunction can be present with very subtle symptoms
and many of the young children had surgical interventions for
the first time [28]. In comparison, only 1 % of children had
abnormal results with the thromboxane A2-specific AA at
baseline, while the Impact-R, like the PFA-100, showed a
significant number of abnormal results (31.6 %) at baseline
(Table 2). At baseline, also 23.8 % had prolonged CTs with
both Col/Epi and Col/ADP CTs (data not shown). The in-
creased rate of abnormal CTs was not investigated further
and other factors (e.g., the problem of standardization of tour-
niquet use in children during difficult blood sampling proce-
dures) might be contributory [37].
PFA-100 CTs have been shown to be highly depen-
dent on levels of plasma VWF that could also influence
the prevalence of AR according to the PFA-100 CTs [9,
21]. Our results confirm that children with AR according
to PFA-100 CTs have significantly increased VWF:RCo
levels compared to children without AR. Data from stud-
ies in adults indicate that VWF can be increased due to
physical and mental stress, which could occur in infants
and children during the blood sampling procedure [18,
39]. All the above mentioned findings could make it
difficult to diagnose AR in individual children by the
use of the PFA-100 CTs alone.
This study has several limitations. As aspirin treat-
ment is the standard of care in our institution, we were
unable to include controls that did not receive aspirin
after ICC. So, as we did not observe any thromboem-
bolic events during our follow-up period, it is unclear if
in children after ICC, aspirin is required at all. This
needs to be studied in future randomized controlled
studies. In addition, follow-up urine samples were avail-
able in 51 % of our patients after ICC, which allows us
to give only approximate data about the agreement of
AA and urinary 11-dhTxB2 excretion.
In conclusion, the results of this pediatric study com-
paring different laboratory tests show an AR prevalence
of 6.7 % according to AA, which is similar to that seen
in recent adult studies [12, 13]. In the majority of cases,
AR could be overcome by an increase in the aspirin
dose. The most specific test for detecting AR is AA,
while PFA-100 CTs and Impact-R SC results have a
lower sensitivity and specificity, and urinary 11-dhTxB2
excretion can be biased by concurrent clinical conditions
or thromboxane production by cells other than platelets.
In this study, an aspirin dose of 2–5 mg/kg was effective
in inhibiting platelet function in the majority of children.
Still, it is unknown if aspirin is required after ICC at all.
This has to be taken into account as a significant number
of children demonstrated bleeding symptoms on aspirin;
although no major bleeding events occurred, minor
bleeding might be even more frequent in younger chil-
dren and when doses >5 mg/kg are applied. In line with
current recommendations for adults, testing for aspirin
response does not appear to be generally indicated in
pediatric patients [25]. Most importantly, pediatricians
should enforce compliance of aspirin intake. However,
testing for aspirin response could be applied in individ-
ual cases, particularly when the thromboembolic risk re-
quires a profound and well-documented inhibition of
platelet thromboxane synthesis, when a possible interac-
tion with food or concomitant medication needs to be
monitored, or when the treating physician wants to apply
an aspirin dose in the lower range, i.e., in order to min-
imize the bleeding risk.
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